Ross Margulies of Manatt Health examines MFN, CMS rulemaking and the global impact of US drug pricing reform on launch sequencing, pricing and market access strategy. 

Drake Reiter of Priority Health discusses MFN, IRA, rebate erosion, MFP commercial spillover and how US pricing reform could reshape value and global launch strategy.

Omar Ali speaks with Jill Hanson of Centene on US pricing reform, value-based contracting, Part B drugs and site-of-care optimisation, with lessons for global access.

A deep dive into MFN pricing in pharma. Learn how price spillover, launch delays, and payer pressure are changing global access strategy.

Omar Ali and Dr Krzysztof Łanda unpack HTA reform, MFN pressures, and Poland’s evolving pricing system shaped by politics, economics, and EU shifts.

Omar Ali and Dr Yousaf Ahmad discuss NHS pricing pressures, VBAs in practice, and how UK access is adapting to MFN and oncology complexities.